Biotech startups that raised Series C in the United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Delix Therapeutics | Boston | Series C | $100.0M | 2026-11-09 |
| BigHat Biosciences | San Mateo | Series C | $75.0M | 2026-09-24 |
| ImmunoPhotonics | St Louis | Series C | $10.1M | 2026-09-01 |
| Bridge to Life | Northbrook | Series C | $110.0M | 2026-08-12 |
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
| Chai Discovery | San Francisco | Series C | $400.0M | 2026-07-14 |
| Cellanome | Redwood City | Series C | $75.9M | 2026-06-18 |
| Triveni Bio | Watertown | Series C | $65.0M | 2026-06-17 |
8 rows of the CSV in 5 of its 18 columns.
- The 339 biotech startups in the United States whose last round is Series C have raised $38.6B in total.
- 29 of them closed their most recent round in the last 12 months, $2.3B combined.
- The largest of those rounds is Chai Discovery's $400.0M Series C, dated July 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- RA Capital Management is an investor in 10 of them, more than any other fund.
- Health care is the most common other sector, with 312 companies (92%).
- 4% were founded in 2020 or later; the median founding year is 2011.
- The most common team size is 11 to 50 employees (45% of companies with a recorded size).
- 3 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 339| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| BigHat Biosciences | BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. | Artificial intelligence | San Mateo | Series C | $75.0M | 2026-09-24 | $174.3M | Andreessen Horowitz, Gaingels, 8VC +2 | 51 to 100 | 2019 |
| ImmunoPhotonics | ImmunoPhotonics is a biotechnology company that develops cancer immunotherapies to stimulate immune responses against tumors. | Biotech | St Louis | Series C | $10.1M | 2026-09-01 | $42.0M | TCA Venture Group, Cultivation Capital, Arch Grants +1 | 11 to 50 | 2012 |
| Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Boston | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Boston | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| Terrestrial Bio | Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. | Biotech | Cambridge | Series C | $50.0M | 2026-03-26 | $180.9M | RA Capital Management, National Institutes of Health, The Engine | 11 to 50 | 2012 |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| Colossal Biosciences Unicorn | Colossal Biosciences uses gene editing technology to pursue de-extinction of species. | Biotech | Austin | Series C | $60.0M | 2026-02-03 | $628.1M | Boost VC, Capital Factory, Climate Capital | 101 to 250 | 2021 |
| Beacon Therapeutics | Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. | Biotech | Alachua | Series C | $75.0M | 2026-01-08 | $365.1M | Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 | 101 to 250 | 2023 |
| Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | San Francisco | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| Lumen Bioscience | Lumen Bioscience discovers, develops, and manufactures biologic drugs and vaccine candidates. | Biotech | Seattle | Series C | $30.0M | 2025-10-08 | $97.0M | US Department of Energy, WestRiver Group | 101 to 250 | 2017 |
| TORL BioTherapeutics | TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. | Biotech | Culver City | Series C | $96.0M | 2025-10-07 | $412.0M | Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 | 51 to 100 | 2018 |
| Kromatid | Kromatid develops molecular cytogenetics assays and reagents to study genetic abnormalities and diseases. | Biotech | Longmont | Series C | $8.0M | 2025-08-20 | $28.1M | BroadOak Capital Partners, First Capital Ventures | 11 to 50 | 2007 |
| Gameto | Gameto develops cell-engineered therapeutics for the female reproductive system. | Biotech | New York | Series C | $44.0M | 2025-08-12 | $117.0M | FJ Labs, Insight Partners, Gaingels +2 | 11 to 50 | 2020 |
| Attovia Therapeutics | Attovia Therapeutics develops biotherapeutics for immune-mediated diseases. | Biotech | San Carlos | Series C | $90.0M | 2025-04-15 | $255.0M | Goldman Sachs Asset Management, Cormorant Asset Management, Marshall Wace +2 | 11 to 50 | 2023 |
| Biolinq | Biolinq develops a wearable biosensor platform that measures blood level information. | Biotech | San Diego | Series C | $100.0M | 2025-03-19 | $276.3M | Alpha Wave Global, Pegasus Tech Ventures, M Ventures | 51 to 100 | 2012 |
| Umoja Biopharma | Umoja Biopharma develops immunotherapies intended to treat cancer by engineering the body's own immune cells. | Biotech | Seattle | Series C | $100.0M | 2025-01-14 | $363.0M | SoftBank Vision Fund, Temasek, Cormorant Asset Management +2 | 101 to 250 | 2019 |
| ArsenalBio | ArsenalBio develops programmable CAR T-cell therapies for solid tumors. | Biotech | South San Francisco | Series C | $325.0M | 2024-09-04 | $630.8M | ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 | 251 to 500 | 2019 |
| MBX Biosciences | MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. | Biotech | Carmel | Series C | $63.5M | 2024-08-05 | $238.4M | New Enterprise Associates, RA Capital Management, OrbiMed +2 | 11 to 50 | 2019 |
| Autobahn Therapeutics | Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. | Biotech | San Diego | Series C | $100.0M | 2024-07-24 | $208.7M | Insight Partners, Invus, Bristol-Myers Squibb +2 | 11 to 50 | 2017 |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. | Biotech | San Mateo | Series C | $182.0M | 2024-05-09 | $242.2M | RA Capital Management, Wellington Management, Novo Holdings +2 | 11 to 50 | 2019 |
| Aardvark Therapeutics | Aardvark Therapeutics develops small molecule drugs for obesity and rare genetic metabolic disorders. | Biotech | San Diego | Series C | $85.0M | 2024-05-09 | $129.0M | Cormorant Asset Management, Vickers Venture Partners, Decheng Capital +1 | 11 to 50 | 2017 |
Table 1. Biotech startups that raised Series C in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 339.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. | Artificial intelligence | San Francisco | Series C | $400.0M | 2026-07-14 | $631.0M | Thrive Capital, OpenAI | 11 to 50 | 2024 |
| 2 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 3 | Bridge to Life | Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. | Biotech | Northbrook | Series C | $110.0M | 2026-08-12 | $167.5M | Perceptive Advisors | 101 to 250 | 2005 |
| 4 | Terremoto Biosciences | Terremoto Biosciences develops medicines using lysine-based covalent chemistry. | Biotech | San Francisco | Series C | $108.0M | 2026-04-15 | $358.0M | OrbiMed, Novo Holdings, Third Rock Ventures +2 | 51 to 100 | 2021 |
| 5 | Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. | Biotech | Cambridge | Series C | $105.0M | 2026-03-05 | $321.8M | Morningside, FoundersX Ventures, IAG Capital Partners +1 | 11 to 50 | 2016 |
| 6 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Boston | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 7 | Loyal | Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. | Biotech | San Francisco | Series C | $100.0M | 2026-02-11 | $237.1M | Khosla Ventures, First Round Capital, Quiet Capital +1 | 101 to 250 | 2019 |
| 8 | CereVasc | CereVasc develops a minimally invasive treatment for communicating hydrocephalus. | Biotech | Charlestown | Series C | $85.0M | 2026-06-04 | $199.0M | Perceptive Advisors, Bain Capital Life Sciences, ATON Partners | 11 to 50 | 2014 |
| 9 | Culture Biosciences | Culture Biosciences provides automated systems for bioprocess development of biological products. | Biotech | San Francisco | Series C | $80.0M | 2025-12-16 | $101.6M | Y Combinator, National Science Foundation, BoxGroup +1 | 101 to 250 | 2016 |
| 10 | Cellanome | Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. | Biotech | Redwood City | Series C | $75.9M | 2026-06-18 | $289.6M | Premji Invest, Synetro Group | 51 to 100 | 2020 |
Table 2. Biotech startups that raised Series C in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 10 | 3% | 2 | Delix Therapeutics, Terrestrial Bio |
| 2 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 8 | 2% | 2 | BigHat Biosciences, Ratio Therapeutics |
| 3 | OrbiMed | Private equity firm | New York, United States | 8 | 2% | 3 | Triveni Bio, Terremoto Biosciences, Aspen Neuroscience |
| 4 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 7 | 2% | 1 | Culture Biosciences |
| 5 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 6 | 2% | 2 | Prellis Biologics, Loyal |
| 6 | Y Combinator | Startup accelerator | Mountain View, United States | 5 | 1% | 1 | Culture Biosciences |
| 7 | Temasek | Private equity firm | Singapore | 5 | 1% | ||
| 8 | Alumni Ventures | Angel group | Manchester, United States | 5 | 1% | ||
| 9 | Gaingels | Syndicate | Burlington, United States | 4 | 1% | 2 | Delix Therapeutics, BigHat Biosciences |
| 10 | Cormorant Asset Management | Hedge fund | Boston, United States | 4 | 1% | 1 | Triveni Bio |
| 11 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 4 | 1% | 2 | Triveni Bio, Aspen Neuroscience |
| 12 | Invus | Private equity firm | New York, United States | 4 | 1% | 1 | Triveni Bio |
| 13 | Insight Partners | Private equity firm | New York, United States | 4 | 1% | ||
| 14 | Wellington Management | Private equity firm | Boston, United States | 4 | 1% | ||
| 15 | T. Rowe Price | Private equity firm | Baltimore, United States | 4 | 1% |
Table 3. Biotech startups that raised Series C in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 312 | 92% | $35.6B |
| Software | 38 | 11% | $6.7B |
| Artificial intelligence | 18 | 5% | $4.3B |
| Hardware | 15 | 4% | $1.8B |
| Energy | 4 | 1% | $245.8M |
| Fintech | 4 | 1% | $543.0M |
Table 4. Biotech startups that raised Series C in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 339 | 100% | $32.5M |
Table 5. Biotech startups that raised Series C in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 26 | 8% |
| San Diego | 26 | 8% |
| Cambridge | 23 | 7% |
| Boston | 14 | 4% |
| Menlo Park | 12 | 4% |
| Austin | 9 | 3% |
| New York | 9 | 3% |
| Seattle | 8 | 2% |
| South San Francisco | 8 | 2% |
| Waltham | 6 | 2% |
| San Carlos | 6 | 2% |
| San Mateo | 5 | 1% |
Table 6. Biotech startups that raised Series C in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 7% | $115.0M |
| October 2026 | 1 | 3% | $62.0M |
| September 2026 | 3 | 10% | $208.1M |
| August 2026 | 1 | 3% | $110.0M |
| July 2026 | 5 | 17% | $551.0M |
| June 2026 | 4 | 14% | $310.9M |
| May 2026 | 2 | 7% | $20.0M |
| April 2026 | 1 | 3% | $108.0M |
| March 2026 | 3 | 10% | $177.0M |
| February 2026 | 2 | 7% | $160.0M |
| January 2026 | 3 | 10% | $320.0M |
| December 2025 | 1 | 3% | $80.0M |
| November 2025 | 1 | 3% | $115.0M |
Table 7. Biotech startups that raised Series C in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 27 | 8% | $2.1B |
| 2025 | 27 | 8% | $1.9B |
| 2024 | 26 | 8% | $2.2B |
| 2023 | 15 | 4% | $808.6M |
| 2022 | 28 | 8% | $2.0B |
| 2021 | 31 | 9% | $2.5B |
Table 8. Biotech startups that raised Series C in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 1% |
| 2020 to 2022 | 12 | 4% |
| 2015 to 2019 | 95 | 28% |
| 2010 to 2014 | 79 | 23% |
| Before 2010 | 149 | 44% |
Table 9. Biotech startups that raised Series C in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 42 | 12% |
| 11 to 50 | 151 | 45% |
| 51 to 100 | 68 | 20% |
| 101 to 250 | 50 | 15% |
| 251 to 500 | 13 | 4% |
| 501 to 1,000 | 6 | 2% |
| 1,001 to 5,000 | 2 | 1% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 3 | 1% |
Table 10. Biotech startups that raised Series C in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in the United States. On 16 November 2026 that is 339 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 339 rows: 18 have no round amount, 0 no city and 21 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United States whose last round is Series C are on the list?
- 339, in the file dated 16 November 2026. 29 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 339 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.